Eli Lilly Challenges EMA Decision on Alzheimer’s Drug ApprovalEli Lilly seeks reexamination of its Alzheimer's drug, Keysunra, after EMA denied approval due to brain swelling concerns.
Lilly’s Weight-Loss Pill Looks Strong in Trials—Ozempic’s Reign in Jeopardy?Eli Lilly's new diabetes pill matches Ozempic's effectiveness, with hopes for regulatory approval and a growing obesity treatment market.
New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side EffectsEli Lilly's Lepodisiran shows a 93.9% reduction in lipoprotein levels, a key heart disease risk factor, in mid-stage trials.
Eli Lilly Moves First in India, Beats Novo in Obesity Drug ShowdownEli Lilly launches Mounjaro in India, targeting a large market and competing with Novo Nordisk's Wegovy for obesity treatment.
Must-Reads
1
Man held after hammer attack at Namyangju karaoke bar
LATEST
2
Movies in theaters this week
LATEST
3
[Robert J. Fouser] 2025: A year of testing and triumph
Eli Lilly Challenges EMA Decision on Alzheimer’s Drug Approval Eli Lilly seeks reexamination of its Alzheimer's drug, Keysunra, after EMA denied approval due to brain swelling concerns.
Lilly’s Weight-Loss Pill Looks Strong in Trials—Ozempic’s Reign in Jeopardy? Eli Lilly's new diabetes pill matches Ozempic's effectiveness, with hopes for regulatory approval and a growing obesity treatment market.
New Drug Cuts Heart Disease Risk by 94%—And Has No Major Side Effects Eli Lilly's Lepodisiran shows a 93.9% reduction in lipoprotein levels, a key heart disease risk factor, in mid-stage trials.
Eli Lilly Moves First in India, Beats Novo in Obesity Drug Showdown Eli Lilly launches Mounjaro in India, targeting a large market and competing with Novo Nordisk's Wegovy for obesity treatment.
Hot Topics